



Universiteit
Leiden
The Netherlands

Towards a patient-driven approach to adverse events of targeted agents in oncology

Boers, C.B.

Citation

Boers, C. B. (2019, September 4). *Towards a patient-driven approach to adverse events of targeted agents in oncology*. Retrieved from <https://hdl.handle.net/1887/77519>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/77519>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/77519> holds various files of this Leiden University dissertation.

Author: Boers, C.B.

Title: Towards a patient-driven approach to adverse events of targeted agents in oncology

Issue Date: 2019-09-04

Towards
a patient-driven approach
to adverse events of targeted agents
in oncology

Christine Bettine Boers

The research presented in this dissertation was performed at the Department of Medical Oncology of Leiden University Medical Center, Leiden, The Netherlands, and the Waterland Hospital, Purmerend, The Netherlands.

The research described in this thesis was funded by Amgen, Bayer, EUSA Pharma, GlaxoSmithKline, Novartis, Pfizer, Roche, and the Impaqt Foundation.

Financial Support for the publication of this dissertation was provided by the Leiden University Medical Center, and support of Gildeprint.

Cover design	Monica Schokkenbroek
Layout	Christine B. Boers-Doets
Printed by	Gildeprint
ISBN	978-94-93117-00-6

© 2019 Impaqt, the *CancerMed* Adverse Event Research & Valorisation Foundation

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage or retrieval system, without permission in writing from the author.

Towards a patient-driven approach to adverse events of targeted agents in oncology

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op woensdag 4 september 2019
klokke 16:15 uur

door

Christine Bettine Boers

geboren te Rheinberg, Duitsland
in 1968

Promotores	Prof. dr. A.J. Gelderblom Prof. dr. A.A. Kaptein
Copromotor	Dr. J.B. Epstein, City of Hope, Duarte, CA, United States
Promotiecommissie	Prof. dr. J.J.M. van der Hoeven, LUMC Prof. dr. W.T.A. van der Graaf, NKI/Radboud Dr. J.R. Kroep, LUMC Dr. W. Uytterlinde, NKI

Contents

01 General introduction	1
02 Oral Adverse Events Associated With Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review. <i>Oncologist</i> 2011;17(1):135-44.	11
03 Mammalian target of rapamycin inhibitor-associated stomatitis. <i>Future Oncol.</i> 2013 Dec;9(12):1883-92.....	29
04 Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. <i>Ann Oncol</i> (2015) 26 (suppl 5): v139-v151.....	45
05 Xerosis and pruritus as major EGFRi-associated adverse events. <i>Support Care Cancer.</i> 2016 Feb;24(2):513-521.	71
06 Translation and linguistic validation of the FACT-EGFRi-18 quality of life instrument from English into Dutch. <i>Eur J Oncol Nurs.</i> 2013;17:802-7.....	87
07 Experiences with the FACT-EGFRi-18 instrument in EGFRi-associated mucocutaneous adverse events. <i>Support Care Cancer</i> , 2013. 21(7): p. 1919-26. ..	101
08 General discussion, summary & future perspectives	115
<i>General discussion and summary</i>	115
<i>Future perspectives</i>	122
<i>References</i>	131
09 Samenvatting (Summary in Dutch)	137
10 About the author	139
<i>Curriculum Vitae</i>	139
<i>List of publications</i>	140
11 Acknowledgements.....	143